At a glance
ClinicalIndex Comparison RecordN/ACompleted· 45 enrolled
Drug / intervention
Mirtoselect® + Meriva® +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Window of Opportunity Trial of Anthocyanin Extract and Phospholipid Curcumin in Subjects With Colorectal Adenoma
In Brief
A clinical study evaluating Mirtoselect® + Meriva® and Placebo for Colorectal Adenoma and Risk Reduction. Completed, enrolled 45 participants across 4 sites.
Detailed Summary
It has been shown that curcumin and cyanidin-3-glucoside (C3G) have anticancer effects. In this clinical trial we compare the affect of their combination vs placebo in a four weeks intervention before endoscopic polypectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Adenoma, Risk Reduction
CountriesItaly
CollaboratorsFondazione Umberto Veronesi, Indena S.p.A
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 2013
Enrollment StartMar 2014
Primary CompletionJan 2019
Study CompletionJun 2022
TodayJul 2026
First PostedSep 23, 2013
Enrollment StartMar 1, 2014
Primary CompletionJan 31, 2019
Study CompletionJun 20, 2022
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 12.8 years ago
Interventions
Mirtoselect® + Meriva®dietary
Placebodietary